MX2021006605A - Composicion farmaceutica que comprende peptidos inhibidores contra la se?alizacion fas, para la prevencion o tratamiento de obesidad, higado graso o esteatohepatitis. - Google Patents

Composicion farmaceutica que comprende peptidos inhibidores contra la se?alizacion fas, para la prevencion o tratamiento de obesidad, higado graso o esteatohepatitis.

Info

Publication number
MX2021006605A
MX2021006605A MX2021006605A MX2021006605A MX2021006605A MX 2021006605 A MX2021006605 A MX 2021006605A MX 2021006605 A MX2021006605 A MX 2021006605A MX 2021006605 A MX2021006605 A MX 2021006605A MX 2021006605 A MX2021006605 A MX 2021006605A
Authority
MX
Mexico
Prior art keywords
obesity
steatohepatitis
fatty liver
inhibitory peptide
prevention
Prior art date
Application number
MX2021006605A
Other languages
English (en)
Inventor
Sang- Kyung Lee
Kunho Chung
Irfan Ullah
Su Min Bae
Jae Yeoung Lim
Original Assignee
Signet Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Signet Biotech Inc filed Critical Signet Biotech Inc
Publication of MX2021006605A publication Critical patent/MX2021006605A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica que comprende un péptido inhibidor contra la señalización de Fas como un ingrediente activo para la prevención o tratamiento de obesidad, hígado graso, o esteatohepatitis; se une específicamente a Fas, que se expresa extensamente en el hígado y tejidos adiposos en un estado obeso, el péptido inhibidor contra la señalización de Fas exhibe altas tasas de suministro a las regiones inflamatorias provocadas por la obesidad e inhibe directamente la señalización de Fas, que es una trayectoria de señalización de inflamación principal, para inhibir una respuesta inflamatoria; por lo tanto, el péptido puede ser usado ventajosamente para aliviar o tratar la obesidad, hígado graso, o esteatohepatitis.
MX2021006605A 2018-12-04 2019-11-14 Composicion farmaceutica que comprende peptidos inhibidores contra la se?alizacion fas, para la prevencion o tratamiento de obesidad, higado graso o esteatohepatitis. MX2021006605A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20180154274 2018-12-04
PCT/KR2019/015585 WO2020116810A1 (ko) 2018-12-04 2019-11-14 Ｆａｓ 신호전달 억제용 펩티드를 포함하는 비만, 지방간 또는 지방간염의 예방 또는 치료용 약학적 조성물

Publications (1)

Publication Number Publication Date
MX2021006605A true MX2021006605A (es) 2021-07-07

Family

ID=70974360

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021006605A MX2021006605A (es) 2018-12-04 2019-11-14 Composicion farmaceutica que comprende peptidos inhibidores contra la se?alizacion fas, para la prevencion o tratamiento de obesidad, higado graso o esteatohepatitis.

Country Status (11)

Country Link
US (1) US20220088115A1 (es)
EP (1) EP3892289A4 (es)
JP (1) JP2022514125A (es)
KR (2) KR102173183B1 (es)
CN (1) CN113164549A (es)
AU (1) AU2019392040A1 (es)
BR (1) BR112021010865A2 (es)
CA (1) CA3121901A1 (es)
MX (1) MX2021006605A (es)
SG (1) SG11202105650RA (es)
WO (1) WO2020116810A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022086039A1 (ko) * 2020-10-19 2022-04-28 주식회사 시그넷바이오텍 Fas 신호전달 억제용 펩타이드를 포함하는 황반변성 예방 또는 치료용 조성물
KR20230057747A (ko) * 2021-10-22 2023-05-02 한양대학교 산학협력단 세포사멸 억제 단백질을 포함하는 허혈성 뇌졸중 예방 또는 치료용 조성물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1513543B1 (en) * 2002-05-23 2010-10-06 The Trustees of The University of Pennsylvania Fas peptide mimetics and uses thereof
WO2009089362A1 (en) * 2008-01-08 2009-07-16 The Trustees Of The University Of Pennsylvania Methods of treatment using agents for regulating fas receptor function in skin and hair related pathologies
KR101646726B1 (ko) * 2013-08-12 2016-08-09 한양대학교 산학협력단 환형 폴리 ｆｔｐ 및 이의 용도
CN108472332B (zh) * 2015-11-13 2022-03-18 汉阳大学校产学协力团 用于通过经鼻施用来治疗中风的组合物

Also Published As

Publication number Publication date
KR20200067745A (ko) 2020-06-12
CA3121901A1 (en) 2020-06-11
WO2020116810A1 (ko) 2020-06-11
EP3892289A4 (en) 2022-09-14
US20220088115A1 (en) 2022-03-24
EP3892289A1 (en) 2021-10-13
SG11202105650RA (en) 2021-06-29
KR20200096449A (ko) 2020-08-12
KR102173183B1 (ko) 2020-11-03
AU2019392040A1 (en) 2021-06-17
CN113164549A (zh) 2021-07-23
BR112021010865A2 (pt) 2021-12-07
JP2022514125A (ja) 2022-02-09

Similar Documents

Publication Publication Date Title
PH12020550857A1 (en) Polycyclic compounds as allosteric shp2 inhibitors
AU2018246796A1 (en) S1PR4-targeting composition for preventing or treating non-alcoholic steatohepatitis
PH12021550985A1 (en) Vesicles derived from lactobacillus paracasei and use of same
PH12018501567A1 (en) New substituted cyanoindoline derivatives as nik inhibitors
MX2021006605A (es) Composicion farmaceutica que comprende peptidos inhibidores contra la se?alizacion fas, para la prevencion o tratamiento de obesidad, higado graso o esteatohepatitis.
MX2017005283A (es) Nuevos derivados de pirazol en calidad de inhibidores de la cinasa inductora de nf-kb (nik).
MX2018008908A (es) Tratamiento para modular la microbiota intestinal.
EA033237B1 (ru) Новые производные пиразолопиримидина в качестве ингибиторов nik, фармацевтическая композиция и лекарственное средство, содержащее ее
MX2017005282A (es) Nuevos compuestos como inhibidores de la cinasa inductora de nf-kb (nik).
MX2018001756A (es) Benzimidazoles sustituidos, su preparacion y su uso como productos farmaceuticos.
MX2019013799A (es) Peptido novedoso y composicion farmaceutica para tratar una enfermedad ocular que comprende el mismo como un ingrediente farmaceutico activo.
PH12015501783A1 (en) Pharmaceutical compositions for the treatment of helicobacter pylori
BR112021023477A2 (pt) Novo composto peptídico, composição farmacêutica para prevenir ou tratar inflamação, composição de alimento para prevenir ou amenizar a inflamação e composição de cosmético tendo um efeito anti inflamatório
MX2019014665A (es) Nuevos derivados de azaindolina sustituida como inhibidores de nik.
TN2015000555A1 (en) Therapeutically active 17-nitrogen substituted estratrienthiazole derivatives as inhibitors of 17.beta.-hydroxysteroid dehydrogenase
WO2019031729A3 (ko) 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 조성물의 비알콜성 단순 지방간 또는 비알콜성 지방간염의 개선 용도
MX2020013692A (es) Compuestos de pirazol e imidazol para la inhibicion de il-17 y rorgamma.
PH12016501548B1 (en) Cholesteryl ester transfer protein (cetp) inhibitor and pharmaceutical compositions comprising said inhibitor for use in the treatment or prevention of cardiovascular diseases
MX2019012522A (es) Compuestos y metodos terapeuticos.
EA201992826A1 (ru) 15бета-[3-пропанамидо]-замещенные эстра-1,3,5(10)-триен-17-оны и их 17-оксимы для применения в ингибировании 17бета-гидроксистероиддегидрогеназ
EP3762005A4 (en) SYNERGIC HERBAL COMPOSITIONS FOR THE TREATMENT OF OBESITY AND OVERWEIGHT
MX2020007368A (es) Composiciones estables de corticosteroides.
MX2019011610A (es) Derivados de quinoxalina y piridoprazina como inhibidores de pi3k-beta.
FI3829535T3 (fi) Koostumuksia ihoinfektioiden ehkäisyyn ja hoitoon
EP3708574A4 (en) PEPTIDE FOR INHIBITION OF SKIN INFLAMMATION AND COMPOSITION OF IT FOR THE PREVENTION OR TREATMENT OF INFLAMMATION OF THE SKIN